Source link : https://newshealth.biz/health-news/bimekizumab-safety-holds-up-in-long-term-data/

Bimekizumab (Bimzelx) is approved for psoriasis, spondyloarthritis (SpA), psoriatic arthritis (PsA), and hidradenitis suppurativa, but has not been on the U.S. market very long. Safety data for conditions other than plaque psoriasis thus far have come from 1-year follow-up in the drug’s clinical studies; this study pooled longer-term data from open-label extensions in SpA and […]

The post Bimekizumab Safety Holds Up in Long-Term Data first appeared on News Health.

—-

Author : News Health

Publish date : 2026-03-12 18:33:00

Copyright for syndicated content belongs to the linked Source.

—-

12345678